Filling A Vaccine Void With Cue Biopharma's Dan Passeri, J.D.
Source: Bioprocess Online
![20_12_BPO_BusBiotech_Social_ep41 20_12_BPO_BusBiotech_Social_ep41](https://vertassets.blob.core.windows.net/image/f61979e5/f61979e5-5aad-4aa4-9760-c30aadbc0a08/375_250-20_12_bpo_busbiotech_social_ep41.png)
CUE Biopharma CEO Dan Passeri, J.D. joins us for a discussion on the development of the company's Immuno-STAT platform for the selective targeting and alteration of T cells. Passeri shares the rationale behind his belief in the company's immunotherapeutic approach, and how the CUE-100 series of candidates in its pipeline are being developed to address a scourge of HPV-related head, neck, and other cancers.
access the Podcast!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
Bioprocess Online
This website uses cookies to ensure you get the best experience on our website. Learn more